New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 24, 2012
06:10 EDTAKRXAkorn announces approval and launch of generic Prometrium
Akorn announced that its manufacturing and development partner, Sofgen Pharmaceuticals has received approval of its abbreviated new drug application, or ANDA, for Progesterone capsules, 100mg and 200mg. The approved ANDA is for the generic of Abbott Laboratories' Prometrium capsules indicated for the treatment of endometrial hyperplasia and secondary amenorrhea. Akorn has exclusive marketing rights to Sofgen's product in the U.S. and the Company has begun distribution. According to IMS Health, Progesterone capsules, 100mg and 200mg, had combined sales of approximately $170M in the U.S. based on annualizing the three months ended August 31. IMS Health sales figures exclude certain customary discounts and incentives.
News For AKRX From The Last 14 Days
Check below for free stories on AKRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
17:55 EDTAKRXRepligen to replace Hi-Tech Pharmacal in S&P 600 as of 4/17
Subscribe for More Information
April 14, 2014
19:01 EDTAKRXAkorn gets FTC clearance for Hi-Tech Pharmacal deal
Akorn (AKRX) announced that the U.S. FTC has voted to approve Akornís acquisition of Hi-Tech Pharmacal (HITK). The unanimous vote in support of the transactions follows Akornís agreement to a proposed consent order requiring divestiture of certain products as a condition to obtaining FTC approval. The parties have now obtained all regulatory approvals required to consummate the acquisition, and intend to close by the end of this week.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use